IRVINE, Calif. - Masimo (NASDAQ: NASDAQ:MASI), a developer of noninvasive monitoring technologies, announced that the U.S. Federal Circuit Court has reinstated an import ban on certain Apple (NASDAQ:AAPL) Watch models. This action upholds the U.S. International Trade Commission's order which found that these models infringed on Masimo's patented pulse oximetry technology.
Joe Kiani, Founder and CEO of Masimo, commented on the court's decision, emphasizing the importance of respecting intellectual property rights and the implications for patient safety.
Masimo has criticized the Apple Watch's pulse oximetry function, claiming it failed to detect over 90% of potentially life-threatening events in a study. Unlike the Apple Watch, Masimo's pulse oximetry technology, including its W1® health watch, has received FDA clearance for medical use.
Masimo's technology is widely used in healthcare, with applications such as preserving newborns' eyesight, detecting congenital heart defects, and monitoring post-surgical patients on opioids. The company asserts that its products, which are utilized on more than 200 million patients annually, contribute to improved patient outcomes and reduced healthcare costs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.